TAIZHOU, China, July  23, 2026  (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the &#34;Company&#34;), today announced that it has entered into a definitive securities purchase agreement with certain

SXTC

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

China SXT raises about $9M via 4.5M units; warrants issued

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>TAIZHOU, China, July  23, 2026  (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the &amp;#34;Company&amp;#34;), today announced that it has entered into a definitive securities purchase agreement with certain</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>China SXT Pharmaceuticals announced a registered direct offering to raise roughly $9 million through 4.5 million units at $2 each, with warrants exercisable at $3.20 for one year. The funding improves near-term liquidity but adds dilution from new shares and warrants. The market will watch for how proceeds are deployed and the likelihood of warrant exercise.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>China SXT Pharmaceuticals to raise about $9M via 4.5M units at $2.00.</li><li>Warrants exercise price set at $3.20; exercisable immediately, expiring in 1 year.</li><li>Closing expected around July 24, 2025, subject to closing conditions.</li><li>Univest Securities, LLC named sole placement agent for the offering.</li><li>Shelf registration Form F-3, effective Dec 1, 2025, facilitates the direct offering.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>China SXT Pharmaceuticals Inc. (SXTC)</strong>: Primary issuer; financing via direct offering; dilution risk to existing holders.</li><li><strong>Univest Securities, LLC (N/A)</strong>: Sole placement agent; facilitates the financing; no direct fundamental impact.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article describes a capital-raising financing that will affect SXTC&#039;s liquidity and share count, influencing valuation and risk in the near term.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>4.5 million new shares potential dilution; immediate share-count impact.</li><li>Warrants exercisable at $3.20; potential cash inflow or further dilution.</li><li>Proceeds about $9 million; use of funds and burn rate clarity pending.</li><li>Close date and regulatory filings anchor next price-to-reaction window.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Offering: 4,500,000 units at $2.00 per unit.</li><li>Each unit: one Class A ordinary share and one warrant.</li><li>Warrant: exercise price $3.20, exercisable immediately, expires in 1 year.</li><li>Gross proceeds: approximately $9 million.</li><li>Closing date: on or about July 24, 2025; Form F-3 shelf filed Dec 1, 2025.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term dilution pressure; warrants could offer upside if exercised; monitor 6–12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>TAIZHOU, China, July  23, 2026  (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SXTC">SXTC</a>) (the "Company"), today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 4,500,000 units (each, a "Unit"), consisting of one Class A ordinary share of the Company, no par value per share (each, a "Class A ordinary share"), and one common warrant (each, a "Warrant"), at a purchase price of $2.00 per Unit in a registered direct offering.</p>  <p>Each of the Warrants will have an exercise price of $3.20 per Class A Class A ordinary share, will be immediately exercisable upon issuance, and will expire on the one year anniversary of the issuance date. The aggregate gross proceeds to the Company of this offering are expected to be approximately $9 million, before deducting placement agent fees and other offering expenses payable by the Company. The transaction is expected to close on or about July 24, 2025, subject to the satisfaction of customary closing conditions.</p>  <p>Univest Securities, LLC is acting as the sole placement agent.</p>  <p>The registered direct offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-291428) previously filed by the Company with the U.S. Securities and Exchange Commission ("SEC") and became effective on December 1, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC&#39;s website located at <a href="https://www.globenewswire.com/Tracker?data=f56z9wZLR12YE3HdBIJGGltYZ3oVXuAA9lM7OgYiPAMyTu57E7oBmrYmnrP5WztT9ikbochMFBD5WCVFZLujpA==" rel="nofollow" target="_blank">http://www.sec.gov</a>. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Univest Securities, LLC at <a href="https://www.globenewswire.com/Tracker?data=wAcUgKK-I0UV4PoPg9CQme79EL3MeN14MOJ0Krc0TVKccqEE-4U_nd9NAhWEfX-XY0EI5PvmntUsRbLYPEDrHA==" rel="nofollow" target="_blank">info@univest.us</a>, or by calling +1 (212) 343-8888.</p>  <p>This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying base prospectus will be filed by the Company and, upon filing, can be obtained at the SEC&#39;s website at <a href="https://www.globenewswire.com/Tracker?data=uCEmrSh0Ys9Yo6z8qDpKNgEl7Y8Otwt_Wxw56ctDUDsg2Z2GJ51zg0sHXfWRS-TQBWJGrdu6K1GjaezpajJOoA==" rel="nofollow" target="_blank">www.sec.gov</a>.</p>  <p><b>About China SXT Pharmaceuticals Inc.</b></p>  <p>Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=uCEmrSh0Ys9Yo6z8qDpKNm9wV5i9gQJgQwEDMo9St-qMLIzY-_lxrs9QghWgu9Js9oeraUp7srxJIVWzxNQsBXzGIf19sGS2TkLGC1NjnHyb0ojmNQU4wD0VlUrT_K4p2nE4LRjLhUOsTZNjcasGDrVmsRcqUV9FaNUC_z5K4jGQmTa1iQoU7VSgoyhpW2Yao3SWT-3iaTJsgZGR4m-im16z_YNJdSRuO22g7aw3DijI4abLJQHAaAkZ3AuwYEAawM5maFnFZqJEeY44WJKbGA==" rel="nofollow" target="_blank">www.sxtchina.com</a>.</p>  <p><b>Forward-Looking Statements</b></p>  <p>Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.</p>  <p><b>China SXT Pharmaceuticals Inc.</b></p>  <p>Feng Zhou, Chief Executive Officer</p>  <p>Email: <a href="https://www.globenewswire.com/Tracker?data=vMfgCEoET-IJ3f4hnNtxZp-58RTUTOCxbSS3VsrtjPy11-4ezXIKLO2MVFR3V8ieuRFPxCKwQfMFPFAzbZRp9XC1HV0hPYLO_RJEgJ80SymAPOHNOjxMLPwUei8sspC5SiVnkOh7uMnql5GBtOdDg90m_ZI59er3No12SWxTz07rLs9Y-aLqGYwVBy9vanTRR7mBP83KrGOgebz2kpNKhysoW7T4mIEPXfyxiObJT_WgPquHCxW9FsVRJY8w4iFxnqYJZmfw3kLYPqaF2UJWxw==" rel="nofollow" target="_blank">fzhou@sxtchina.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc2NzA2OSM3NzIwMTgyIzUwMDA5OTEzNw=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MDZlZWU0YjYtYTQyMi00ZmEzLThlNDktYTlmOGUzNjI2YzQ1LTUwMDA5OTEzNy0yMDI2LTA3LTIzLWVu/tiny/China-SXT-Pharmaceuticals-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/6a00274b-2919-48d2-bb84-e9968402a2fc"><img src="https://ml.globenewswire.com/media/6a00274b-2919-48d2-bb84-e9968402a2fc/small/chinasxt-jpg.jpg" border="0" width="150" height="71" alt="Primary Logo"></img></a></p>

China SXT Pharmaceuticals announced a registered direct offering to raise roughly $9 million through 4.5 million units at $2 each, with warrants exercisable at $3.20 for one year. The funding improves near-term liquidity but adds dilution from new shares and warrants. The market will watch for how proceeds are deployed and the likelihood of warrant exercise.

News insight

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

AI summary

Sentiment rationale

Key facts

Corporate Developments